MwanzoATYR • NASDAQ
add
aTyr Pharma Inc
$ 3.03
Baada ya Saa za Kazi:(1.98%)+0.060
$ 3.09
Imefungwa: 22 Nov, 17:03:35 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 2.98
Bei za siku
$ 2.95 - $ 3.19
Bei za mwaka
$ 1.42 - $ 3.19
Thamani ya kampuni katika soko
254.35M USD
Wastani wa hisa zilizouzwa
1.28M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 3.34M | 25.93% |
Mapato halisi | -17.26M | -52.20% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.23 | -15.00% |
EBITDA | -17.96M | -44.42% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 65.99M | -35.39% |
Jumla ya mali | 91.62M | -26.75% |
Jumla ya dhima | 26.48M | -1.45% |
Jumla ya hisa | 65.14M | — |
hisa zilizosalia | 83.94M | — |
Uwiano wa bei na thamani | 3.47 | — |
Faida inayotokana na mali | -45.92% | — |
Faida inayotokana mtaji | -52.14% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -17.26M | -52.20% |
Pesa kutokana na shughuli | -13.16M | -37.65% |
Pesa kutokana na uwekezaji | 17.95M | 309.45% |
Pesa kutokana na ufadhili | elfu -105.00 | -103.91% |
Mabadiliko halisi ya pesa taslimu | 4.68M | 287.77% |
Mtiririko huru wa pesa | -6.49M | -12.66% |
Kuhusu
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Ilianzishwa
1 Jan 2005
Tovuti
Wafanyakazi
58
